Allarity Therapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	S-1/A	S-1/A	S-1/A	S-1/A
Revenues	6.9	14.2	0.0	0.1
Revenue growth	-51.2%		-100.0%
Cost of goods sold	6.9	14.2	0.0	0.0
Gross profit	0.0	0.0	0.0	0.1
Gross margin	0.0%	0.0%		100.0%
Selling, general and administrative [+]	10.0	12.4	4.1	3.9
General and administrative	10.0	12.4	4.1	3.9
Research and development			5.1	6.4
Other operating expenses	6.9	14.2	-0.8
EBITDA [+]			-8.3	-10.1
EBITDA growth	-36.4%	218.6%	-17.2%
EBITDA margin	-243.8%	-187.1%		-8388.3%
Depreciation and amortization			0.0	0.1
EBIT [+]	-16.9	-26.6	-8.4	-10.1
EBIT growth	-36.4%	216.8%	-17.1%
EBIT margin	-243.8%	-187.1%		-8430.8%
Non-recurring items [+]	17.6		0.8	7.5
Asset impairment	17.6			7.5
Interest expense, net [+]	0.0		0.2	3.3
Interest expense			0.2	3.3
Interest income	0.0
Other income (expense), net [+]	16.9	0.0	4.4	6.5
Gain (loss) on investments			-0.7
Gain (loss) on foreign currency transactions			-0.1	-0.1
Other			-2.0	1.4
Pre-tax income	-17.6	-26.5	-5.1	-14.4
Income taxes	-1.5	0.1	2.2	4.6
Tax rate	8.7%
Minority interest			0.0	-0.1
Net income	-16.1	-26.6	-7.2	-18.9
Net margin	-231.7%	-187.7%		-15741.7%

Basic EPS [+]	($0.06)	($0.15)	($0.04)	($0.30)
Growth	-59.8%	250.9%	-86.0%
Diluted EPS [+]	($0.06)	($0.15)	($0.04)	($0.30)
Growth	-59.8%	250.9%	-86.0%

Shares outstanding (basic) [+]	272.2	181.7	172.7	63.4
Growth	49.8%	5.2%	172.4%
Shares outstanding (diluted) [+]	272.2	181.7	172.7	63.4
Growth	49.8%	5.2%	172.4%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.